HEALTHJul 2 · 13:25 UTCSTAT NEWSEd Silverman

STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more

A U.S. judge blocked Colorado from capping the price of Amgen's Enbrel, citing potential harm to the company, while a new Medicare program will offer obesity drugs at $50/month. Novo Nordisk and Eli Lilly's weight-loss treatments will be included in the trial.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

AmgenorganizationNovo NordiskorganizationEli LillyorganizationColorado Prescription Drug Affordability BoardorganizationU.S. Centers for Medicare & Medicaid ServicesorganizationEnbreltopicWegovytopicZepboundtopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 5 · 09:30 UTC
A pharmaceutical company is trying to block Colorado’s first-in-the-nation drug price cap in court
HEALTHMay 19 · 13:23 UTC
STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
HEALTHMay 18 · 14:43 UTC
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
HEALTHJun 16 · 13:32 UTC
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, Germany’s pricing plans, and more